申请人:Eli Lilly and Company
公开号:US05488058A1
公开(公告)日:1996-01-30
The present invention provides pharmaceutically active compounds of formula I ##STR1## wherein R.sup.1 is --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), or --OSO.sub.2 (C.sub.2 -C.sub.6 alkyl); R.sup.2 is --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), --OSO.sub.2 (C.sub.2 -C.sub.6 alkyl), or halo, providing when Z is --S--, R.sup.2 is not halo; R.sup.3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3; and z is --O-- or --S--; or a pharmaceutically acceptable salt thereof, for inhibiting restenosis.
本发明提供了化学式I的药用活性化合物##STR1##其中R.sup.1为--H,--OH,--O(C.sub.1 -C.sub.4烷基),--OCOC.sub.6 H.sub.5,--OCO(C.sub.1 -C.sub.6烷基),或--OSO.sub.2(C.sub.2 -C.sub.6烷基);R.sup.2为--H,--OH,--O(C.sub.1 -C.sub.4烷基),--OCOC.sub.6 H.sub.5,--OCO(C.sub.1 -C.sub.6烷基),--OSO.sub.2(C.sub.2 -C.sub.6烷基),或卤素,当Z为--S--时,R.sup.2不是卤素;R.sup.3为1-哌啶基,1-吡咯啉基,甲基-1-吡咯啉基,二甲基-1-吡咯啉基,4-吗啉基,二甲胺基,二乙胺基,二异丙胺基,或1-己亚甲基亚胺基;n为2或3;z为--O--或--S--;或其药用可接受盐,用于抑制再狭窄。